Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setmelanotide - Rhythm

Next Previous
X
Search
Drug Profile

Setmelanotide - Rhythm

Alternative Names: BIM-22493; CAM 4072; IMCIVREE; RM-493

Latest Information Update: 25 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Developer Rhythm
  • Class Amides; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Obesity
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity

Most Recent Events

  • 20 Dec 2024 the US FDA approves in setmelanotide for Obesity (In adolescents, In children, In the elderly, In adults) (aged 2 years and older) in USA (SC)
  • 03 Dec 2024 MHRA approves expands Marketing Authorization for Obesity of Setmelanotide for pediatric patients as young as 2 years old in United Kingdom (SC)
  • 18 Nov 2024 Rhythm Pharmaceuticals plans a 34-week substudy in Obesity (In children, In adolescents, In adults, In the elderly) (SC) in the first quarter of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top